Nurix Therapeutics, Inc.
General ticker "NRIX" information:
- Sector: Health Care
- Industry: Biotechnology
- Capitalization: $1.1B (TTM average)
Nurix Therapeutics, Inc. follows the US Stock Market performance with the rate: 11.3%.
Estimated limits based on current volatility of 4.0%: low 16.50$, high 17.86$
Factors to consider:
- Total employees count: 286 as of 2024
- Top business risk factors: Drug development risks, Labor/talent shortage/retention, Operational and conduct risks, Regulatory and compliance, Cybersecurity threats
- Price in estimated range
- Earnings for 9 months up through Q3 are close to our estimates
Stock Forecast*
* forecast is subjective and experimental, should not be used for any investment decisions
Long term estimates were made for the period from 2024-11-30 to 2026-11-30
- 2024-11-30 to 2025-11-30 estimated range: [13.63$, 33.01$]
- 2025-11-30 to 2026-11-30 estimated range: [9.67$, 24.77$]
Financial Metrics affecting the NRIX estimates:
- Negative: with PPE of -7.6 at the end of fiscal year the price was very high
- Negative: negative Operating income
- Negative: Operating cash flow per share per price, % of -11.65 <= 0.33
- Negative: negative Industry operating cash flow (median)
- Positive: Inventory ratio change, % of -2.84 <= -0.75
- Positive: Shareholder equity ratio, % of 78.73 > 63.39
- Positive: Interest expense per share per price, % of 0 <= 0.01
Short-term NRIX quotes
Long-term NRIX plot with estimates
Financial data
| YTD | 2022-11-30 | 2023-11-30 | 2024-11-30 |
|---|---|---|---|
| Operating Revenue | $38.63MM | $76.99MM | $54.55MM |
| Operating Expenses | $222.49MM | $232.05MM | $267.58MM |
| Operating Income | $-183.87MM | $-155.06MM | $-213.03MM |
| Non-Operating Income | $3.51MM | $11.12MM | $19.73MM |
| R&D Expense | $184.50MM | $189.15MM | $221.63MM |
| Income(Loss) | $-180.36MM | $-143.95MM | $-193.30MM |
| Taxes | $0.00MM | $0.00MM | $0.27MM |
| Profit(Loss)* | $-180.36MM | $-143.95MM | $-193.57MM |
| Stockholders Equity | $303.70MM | $200.49MM | $526.99MM |
| Inventory | $1.10MM | $0.00MM | $0.00MM |
| Assets | $416.76MM | $355.60MM | $669.34MM |
| Operating Cash Flow | $-159.81MM | $-81.36MM | $-172.58MM |
| Capital expenditure | $12.24MM | $8.40MM | $9.27MM |
| Investing Cash Flow | $27.20MM | $68.30MM | $-257.71MM |
| Financing Cash Flow | $117.19MM | $3.22MM | $485.67MM |
| Earnings Per Share** | $-3.71 | $-2.65 | $-2.88 |
* Profit(Loss) attributable to entity.
** EPS are Split Adjusted, recent splits may be reflected with a delay.